The table below shows C4 Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$98.69M
-$65.16M
-$106.84M
-$105.94M
-$86.97M
-$67.25M
Capital expenditure
$607.00K
$180.00K
$1.71M
$5.50M
$1.28M
$650.00K
Investing cash flow
-$8.60M
-$51.27M
$158.35M
$58.42M
-$189.34M
-$190.50M
Dividends paid
-
-
-
-
CCCC operating cash flow (10-K history)
C4 Therapeutics, Inc. reported operating cash flow of -$98.69M for fiscal year 2025. That is down 51.5% from -$65.16M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $55.61M (FY 2019) to -$98.69M. Figures come from the company's audited annual reports as filed with the SEC.